Basaloid carcinoma on a perianal fistula

Unidad de Anatomía Patológica, Hospitales de Alta Resolución de Utrera y Constantina-Sierra Norte, Sevilla, España.
Cirugía Española (Impact Factor: 0.89). 07/2009; 87(2):116-7. DOI: 10.1016/j.ciresp.2009.02.011
Source: PubMed
Download full-text


Available from: Pastor Roldan, Apr 04, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cloacogenic zone of the anal canal is a vestigial remnant of the cloacal membrane. This region corresponds to the columnae anales and anal glands. The epithelial lining of the anal glands and of the cloacogenic zone is of the transitional variety. The anal glands are well known to the surgeon because of their role in the pathogenesis of perianal abscesses and fistula in ano. Tumors arising from the cloacogenic zone of the anal canal are rare. In most instants these carcinomas have characteristic clinicopathological features. These lesions are named transitional cloacogenic carcinoma. The therapy of choice is an abdominal-perineal rectum amputation with wide excision of the perineal soft tissue. Inguinal node dissection is indicated if the nodes appear clinically involved. No conclusions have been reached to determine the radiosensitivity of cloacogenic carcinomas. Five cases of cloacogenic carcinoma are reported and the clinicopathological and therapeutic aspects discussed.
    The Netherlands journal of surgery 04/1982; 34(1):21-6.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The total experience at Memorial Sloan-Kettering Cancer Center with two types of anal cancers--squamous and malignant melanoma--is reviewed. The squamous type is much more common, and its anatomic distinction between that of the anal margin and the anal canal is important in its respective clinical and surgical management. The historical, purely surgical management of canal lesions has evolved into the current chemoirradiation management, followed by the surgical approach with improvement of the 5-year survival rate and salvage of rectums. Malignant melanoma, which is the much rarer anal cancer, is still occasionally salvageable, with the use of standard abdominoperineal resection.
    Cancer 10/1992; 70(5 Suppl):1384-9. DOI:10.1002/1097-0142(19920901)70:3+3.0.CO;2-0 · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancers of the anal canal are a rare and diverse group of tumors of the gastrointestinal tract currently managed most often with surgery, chemoradiotherapy, or both. Previous investigations of cancer of the anal canal have reported on small numbers of patients, included only squamous histology, or included a select group of patients. The current study reviewed a large consecutive series of patients with cancer of the anal canal, including all histologies, who received chemoradiotherapy as the primary treatment modality. The spectrum of pathology, treatment, and outcomes for 192 patients with malignant tumors of the anal canal over a 10-year period, from 1984 to 1994, was analyzed. Patient charts were reviewed for diagnosis, staging, treatment, survival, and recurrence rates. The pathologies of 192 patients (mean age, 58 years; 119 females and 73 males) included 143 (74%) with squamous cell carcinoma, 36 (19%) with adenocarcinoma, and 7 (4%) with melanoma. The remaining 6 patients (3%) were diagnosed with neuroendocrine tumors (2), carcinoid tumor (1), Kaposi sarcoma (1), leiomyosarcoma (1), or lymphoma (1). T classification distributions were T1 (3%), T2 (46%), T3 (28%), and T4 (12%). The overall crude 5-year survival and recurrence rates were 53% and 34%, respectively. Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma. Five-year survival rates by T classification were T1 (62%), T2 (57%), T3 (45%), and T4 (17%). Twenty-one (15%) of the patients with squamous cell carcinoma underwent surgical therapy only, with a 5-year survival rate of 60% and a recurrence rate of 23% at 5 years. The remaining 122 patients (85%) with squamous cell carcinoma received chemoradiotherapy only, with a 5-year survival rate of 55% and a recurrence rate of 34% at 5 years. Salvage abdominal perineal resection for recurrent or persistent squamous cell carcinoma after chemoradiotherapy was performed on 13 patients, with 8 (62%) of them alive at a mean follow-up of 32 months. Twenty-two patients (61%) with adenocarcinoma of the anal canal were treated with surgery, and 14 patients (39%) underwent surgery with adjuvant chemoradiation therapy. The 5-year survival and recurrence rates were 63% and 21%, respectively. Chemoradiotherapy for patients with squamous cell carcinoma offers survival rates equivalent to surgical therapy and preserved sphincter function. Adenocarcinoma managed with surgery, with adjuvant therapy for selected patients, gives good results. Melanoma continues to be associated with a poor prognosis.
    Cancer 05/1999; 85(8):1686-93. DOI:10.1002/(SICI)1097-0142(19990415)85:83.0.CO;2-7 · 4.90 Impact Factor